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HIGHLIGHTS 14 
• Chimeras combining 11 residue peptidomimetics and α-conotoxins are potent GLP-1R 15 
agonists. 16 
• Several chimeras had improved biophysical properties compared to the parent compounds. 17 
• These bicyclic peptidomimetics provide a new avenue in the development of GLP-1R 18 
agonists.  19 
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ABBREVIATIONS 20 
T2DM: type-2 diabetes mellitus, GLP-1R: glucagon-like peptide-1 receptor, GLP-1: glucagon-like 21 
peptide-1, GIP: glucose-dependent insulinotropic polypeptide, cAMP: cyclic adenosine 22 
monophosphate, HCTU: 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3 tetramethylaminium 23 
hexafluorophosphate, DIPEA: N,N-diisopropylethylamine, DMF: N,N-dimethylformamide, HATU: 24 
1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate, 25 
Rg: radius of gyration, PSA: polar surface area, SA: surface area, vLogP: virtual log n-octanol/water 26 
partition coefficient. 27 
28 
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GRAPHICAL ABSTRACT 29 
30 
  31 
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ABSTRACT 32 
Type 2 diabetes mellitus (T2DM) results from compromised pancreatic β-cell function, reduced 33 
insulin production, and lowered insulin sensitivity in target organs resulting in hyperglycemia. The 34 
GLP-1 hormone has two biologically active forms, GLP-1-(7-37) and GLP-1-(7-36)amide, which are 35 
equipotent at the glucagon-like peptide-1 receptor (GLP-1R). These peptides are central both to 36 
normal glucose metabolism and dysregulation in T2DM. Several structurally modified GLP-1 37 
analogues are now approved drugs, and a number of other analogues are in clinical trials. None of 38 
these compounds is orally bioavailable and all require parenteral delivery. Recently, a number of 39 
smaller peptidomimetics containing 11–12 natural and unnatural amino acids have been identified that 40 
have similar insulin regulating profiles as GLP-1. The α-conotoxins are a class of disulfide rich 41 
peptide venoms isolated from cone snails, and are known for their highly constrained structures and 42 
resistance to enzymatic degradation. In this study, we examined whether 11-residue peptidomimetics 43 
incorporated into α-conotoxin scaffolds, forming monocyclic or bicyclic compounds constrained by 44 
disulfide bonds and/or backbone cyclization, could activate the GLP-1 receptor (GLP-1R). Several 45 
compounds showed potent (nanomolar) agonist activity at GLP-1R, as evaluated via cAMP signaling. 46 
In addition, HPLC retention times and in silico calculations suggested that mono- and bicyclic 47 
compounds had more favorable n-octanol/water partition coefficients according to the virtual partition 48 
coefficient model (vLogP), while maintaining a smaller radius of gyration compared to corresponding 49 
uncyclized peptidomimetics. Our findings suggest that cyclic peptidomimetics provide a potential 50 
avenue for future design of potent, compact ligands targeting GLP-1R and possessing improved 51 
physicochemical properties. 52 
 53 
KEYWORDS 54 
Glucagon-like peptide-1; Exendin-4; Conotoxins; Glucagon-like peptide-1 Receptor; Type-2 diabetes 55 
mellitus.  56 
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INTRODUCTION 57 
The rapid increase in the incidence of type 2 diabetes mellitus (T2DM) is resulting in a growing 58 
economic burden for health care systems globally. There are around 350 million diabetes sufferers [1] 59 
accounting for 6% of the total mortality rates worldwide [2], 90% of which are T2DM [3]. The cost 60 
associated with diabetes was over 376 billion USD in 2010 and is estimated to rise to 490 billion USD 61 
in 2030 [4]. Consequently, there is an urgent need for the development of new T2DM therapeutics 62 
with differentiation and improvement over those currently available.  63 
 T2DM is characterized by hyperglycemia resulting from compromised pancreatic β-cell 64 
function and reduced insulin production in conjunction with lowered insulin sensitivity in target 65 
organs [5]. Central to both the physiology of glucose metabolism and the pathophysiology of T2DM 66 
are the endogenously-produced incretin peptide hormones glucagon-like peptide-1 (GLP-1; Figure 67 
1A) and glucose-dependent insulinotropic polypeptide (GIP) [6]. GLP-1 and GIP are secreted by cells 68 
lining the gastrointestinal tract in response to nutrient intake, and stimulate pancreatic β-cells to 69 
produce insulin. The incretins account for up to 70% of the prandial insulin response [7], and although 70 
both incretins are secreted at lower levels in T2DM patients, only GLP-1 retains its potent 71 
insulinotropic activity [8]. Consequently, GLP-1 or synthetic GLP-1 analogues have received 72 
considerable interest as leads for the development of T2DM therapeutics [9, 10]. GLP-1 is the product 73 
of posttranslational processing of the preproglucagon gene and is initially produced as GLP-1(1-37), 74 
before undergoing N-terminal truncation into the two equipotent products GLP-1(7-37) and GLP-1(7-75 
36)-amide [11], hereafter described using the generic term ‘GLP-1’.  76 
The physiological effect of GLP-1 is not limited to insulin release, and includes inhibition of 77 
β-cell apoptosis, glucagon secretion, food intake and gastric emptying while promoting β-cell 78 
neogenesis, glucose disposal and cardiac function [7]. GLP-1 signaling primarily occurs through the 79 
G protein-coupled receptor, glucagon-like peptide-1 receptor (GLP-1R) [12]. GLP-1R signaling has 80 
been shown to involve multiple G protein-coupled pathways, including Gαs, Gαi, Gαo and Gαq/11 [13, 81 
14]. Most studies of pathways have measured Gαs coupling and increases in intracellular cAMP [15], 82 
protein kinase A and cAMP-regulated guanine nucleotide exchange factors [16]. Recent studies have 83 
also shown that (G-protein independent) β-arrestin-mediated pathways are important for downstream 84 
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modulation of the response to GLP-1 [17, 18]. It has become increasingly evident that GLP-1 85 
achieves its biological effects through an exquisite balance between different signaling pathways, and 86 
to date no small-molecule GLP-1R agonists have accomplished this [19-22]. In contrast, a number of 87 
modified GLP-1 analogues have been shown to be as effective as GLP-1, and several are currently in 88 
clinical use or in clinical trials [9]. 89 
The first GLP-1R agonist to be approved for clinical use was exenatide (Byetta©), based on a 90 
GLP-1 analogue exendin-4 (Ex-4; Figure 1A) isolated from the saliva of the Gila monster (H. 91 
suspectum) [23]. GLP-1 shares 50% sequence identity with Ex-4, although the latter is a slightly more 92 
potent GLP-1R agonist than GLP-1 [24] and is more resistant to protease degradation in vivo [25]. 93 
Another approved GLP-1R agonist is liraglutide, a human GLP-1 analogue that has an added fatty 94 
acid moiety, which promotes albumin binding, improves circulation half-life, and confers resistance to 95 
protease degradation [26]. Agents currently available to T2DM patients need to be administrated 96 
subcutaneously either daily or weekly; however, a number of formulations based on GLP-1 or 97 
exenatide that allow dosing either one a week or month are currently in clinical trials [27]. Developing 98 
a GLP-1R agonist that is suitable for oral delivery is likely to increase patient compliance and is, 99 
therefore, highly desirable.  100 
Recently an 11-amino acid peptidomimetic analogue based on the first nine residues of the N-101 
terminus of GLP-1, with C-terminal biphenyl derivatives in position 10 and 11, was reported 102 
(BMS21; Figure 1B) [28]. BMS21 exhibited activity at low picomolar concentrations in cAMP 103 
signaling in vitro (EC50 = 0.087 ± 0.04 nM) and activity in an obese mouse model [28]. However, the 104 
signaling profile via various pathways in vitro is quite different to that of GLP-1, with a reduced G-105 
protein-independent β-arrestin1/2-smediated response [29]. Additional work exploring variants of this 106 
peptide with substitutions at positions 10 and 11 led to the identification of a peptide where homo-107 
homo-Phe replaced (2’-Me)-Biphenyl at position 11 in BMS21 (compound 1; Figure 1B). This 108 
peptide displayed similar cAMP signaling activity in vitro and plasma glucose lowering activity in 109 
vivo as BMS21, but with a simplified route of synthesis [30, 31]. With the goal of obtaining an orally 110 
bioavailable variant, compound 13 was extended with Val N-terminally to target active transport by 111 
the PEPT1 transporter [32]. The resulting 12mer peptide (CYOG1) showed oral efficacy in several 112 
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preclinical diabetes models, including insulin release in ob/ob mice at similar levels to that of 113 
subcutaneous exenatide [33].  114 
Peptide-based drugs typically have low bioavailability resulting from poor absorption across 115 
the gut wall, in conjunction with degradation by endogenous proteases in the digestive and circulatory 116 
systems. In general, disulfide-rich peptides are more resistant to chemical or enzymatic insult than 117 
unconstrained peptides. Conotoxins are such disulfide-rich peptides isolated from marine cone snail 118 
venoms that target nicotinic acetylcholine receptors. One such α-conotoxin, Vc1.1, isolated from the 119 
snail Conus victoriae [34], was found to activate GABAB receptors implicated in pain responses [35]. 120 
Recently an engineered cyclic variant of Vc1.1 (cVc1.1; Figure 1C) was shown to have oral efficacy 121 
in a rat model of neuropathic pain [36]. Another α-conotoxin, pc16a (Figure 1D), first isolated from 122 
the cone snail Conus pictus [37], shares several properties with GLP-1 and Ex-4: both classes of 123 
peptides have a flexible N-terminus followed by an α-helix, and target membrane receptors.  124 
We recently reported a series of potent cyclic derivatives of 1 where the peptidomimetic was 125 
constrained by either lactam bridges between residues 5 and 9 or by disulfide bridges formed by 126 
cysteine analogues between residues 2 and 5 [38]. In this study, we produced a series of chimeric 127 
peptides by grafting BMS21/compound 1 analogues into mono- and bicyclic cVc1.1 and pc16a α-128 
conotoxin frameworks. The resulting bicyclic peptides showed nanomolar to micromolar cAMP 129 
activity. This is the first report of such potent bicyclic peptidomimetics and provides a new avenue for 130 
exploring highly constrained cyclic GLP-1R agonists. 131 
 132 
METHODS AND MATERIALS 133 
Peptide Synthesis 134 
Peptides were assembled on rink-amide (0.59 mmol/g; Chem-Impex) or 2-chlorotrityl resins (0.80 135 
mmol/g; Chem-Impex) at a 0.25 mmol scale using Fmoc solid-phase peptide synthesis on a 136 
Symphony Multiplex Synthesizer. Fmoc-protected amino acids (4 eq.) were coupled using 4 eq. 2-(6-137 
chloro-1H-benzotriazole-1-yl)-1,1,3,3 tetramethylaminium hexafluorophosphate (HCTU) and 8 eq. 138 
N,N-diisopropylethylamine (DIPEA) in N,N-dimethylformamide (DMF; 2 x 10 min). Fmoc 139 
deprotection was carried out using 30% piperidine in DMF (2 x 3 min). The following protecting 140 
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groups were used: Trt or acetamidomethyl (Acm) (Cys, His, Asn, and Gln), tBu (Asp, Glu, Ser, Thr, 141 
and Tyr), Boc (Lys and Trp), and Pbf (Arg).  142 
Non-standard Fmoc amino acids were obtained from Chem-Impex International Inc. (Fmoc-143 
p-phenyl-L-Phenylalanine and Fmoc-a-aminoisobutyric acid), ChemPep Inc. (Fmoc-S-trityl-L-144 
penicillamine) and Alabiochem Tech. Co. Ltd (Fmoc-Abu-OH). (S)-2-(((9H-fluoren-9-145 
yl)methoxy)carbonyl-amino)-3-(2'-ethyl-4'-methoxybiphenyl-4-yl)propanoic acid (Fmoc-Bip(2'-Et,4'-146 
OMe)-OH), Fmoc-(S)-2-Fluoro-R-methylphenylalanine (α-Me-(2-F)-Phe) and Fmoc-(S)-2-6-147 
difluoro-R-methylphenylalanine (α-Me-(2-6-di-F)-Phe were synthesized, as previously described 148 
[28]. Extended coupling times were used for the non-standard Fmoc protected amino acids: S-trityl-L-149 
penicillamine ((β,β-di-Me)-Cys), (S)-2-amino-3-(2’ethyl-4-methoxy-[1,1’-biphenyl]4-yl)propanoic 150 
acid ((2’-Et, 4’-OMe)-BIP), (S)-2-amino-5-phenylpentanoic acid (hh-Phe), (S)-2-amino-2-methyl-3-151 
phenylpropanoic acid (α-Me-Phe), (S)-2-amino-3-(2-fluorophenyl)propanoic acid (α-Me-(2-F)-Phe) 152 
and (S)-2-amino-3-(2,6-difluorophenyl)propanoic acid (α-Me-(2,6-di-F)-Phe). Non-standard Fmoc 153 
protected amino acids were coupled with 1.5 eq. amino acid, 1.5 eq. 1-154 
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate 155 
(HATU) and 3 eq. DIPEA for 1 h. Any amino acid following α-Me-Phe, α-Me-(2-F)-Phe and α-Me-156 
(2,6-di-F)-Phe was particularly difficult and coupling was performed with 20 eq. amino acid, 20 eq. 157 
HATU and 40 eq. DIPEA for 18 h followed by standard 4 eq. amino acid, 4 eq. HCTU and 8 eq. 158 
DIPEA (3 x 1 h) and acetylation of unreacted sites. Assembled peptides were liberated from the resin 159 
and side chain deprotected using trifluoroacetic acid (TFA): triisopropylsilane: H2O (95: 2.5: 2.5) over 160 
2 h, before precipitation with ice-cold diethyl ether and lyophilization from acetonitrile/water 161 
mixtures containing 0.1% TFA. 162 
 Peptides were purified by HPLC (Shimadzu Prominence System) on a Phenomenex Jupiter 163 
5µm (250 x 50 mm) column. Peptide purities (>95%) were confirmed using a Phenomenex Jupiter 164 
5µm (150 x 2) mm column and peptide masses were determined by electrospray ionization MS 165 
(Shimadzu Prominence). Removal of the Cys Acm protecting groups and disulfide bond formation 166 
was achieved by dissolving peptide (0.5–1.0 mg/mL) in 80% aqueous acetic acid containing 1 mg/mL 167 
iodine. Alternatively, if the reaction proceeded slowly, acetic acid was substituted for methanol. The 168 
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reaction was monitored by MS, as described above, and was terminated by the addition of ascorbic 169 
acid until the iodine coloration disappeared. Correct disulfide bond folding was monitored by 1H 170 
NMR (Figure S1).  171 
 172 
CHO cAMP Accumulation Assay  173 
CHO K1 cells stably transfected with hGLP-1R were grown at 37°C, 95% O2 and 5% CO2 in 75 cm 174 
flasks containing DMEM/F12 (1:1) media with added 1% GlutaMAX™ (Gibco®), 1% PenStrep and 175 
1% Geneticin® (Gibco®) and grown until 90% confluent. Cells were then washed (PBS), lifted with 176 
cell dissociation solution (Sigma Aldrich), counted and used for cAMP accumulation assays and/or 177 
passaging (1:10). Following the manufacturer’s instructions for the LANCE® Ultra cAMP assay 178 
(Perkin Elmer), cells transfected with hGLP-1R were centrifuged (1500 rpm, 5 min), re-suspended in 179 
cAMP assay buffer (HBSS, 5.56 mM glucose, 0.1% BSA, 0.5 mM IBMX, 5 mM HEPES), and 180 
seeded at 1000 cells per well in a ProxiPlate-384 Plus plate (Perkin Elmer). Cells were treated with 181 
compounds diluted in assay buffer over a range of concentrations (10 µM to 100 fM) and incubated 182 
for 30 min. Cell lysis buffers (Tracer (1:50) and Ulight (1:150)) were added to each well,  and the 183 
places were incubated at room temperature for 2 h, before being read on a PHERAstar FS (BMG 184 
Labtech). Raw signals from three technical replicates were normalized as percentage of GLP-1 185 
maximum before determining EC50 values using GraphPad Prism 6 from three independent 186 
experiments. 187 
 188 
Molecular Modeling 189 
The compounds were solvated in TIP3P water and 70% (v/v) dimethyl sulfoxide neutralized with 190 
Na+/Cl- counter ions using YASARA 13.9.8 [39] (systems consisted of 5000-6000 atoms, including 191 
500–600 solvent molecules), and topologies were generated in VMD 1.9.2. Simulations were 192 
performed in NAMD 2.10 CUDA [40] with CHARMM27 force field parameters. Force field 193 
parameters for dimethyl sulfoxide and synthetic amino acids were constructed using CGenFF 2b8 [41] 194 
as a template, except for Aib (aa6) where SwissParam (http://www.swissparam.ch/) was used. Each 195 
system was equilibrated using a stepwise relaxation procedure under NPT (conserved substance (N), 196 
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pressure (P) and temperature (T)) conditions, as previously described [42]. The particle mesh Ewald 197 
algorithm was used to compute long-range electrostatic interactions at every time step and non-198 
bonded interactions were truncated smoothly between 10.5 Å and 12 Å. All covalent hydrogen bonds 199 
were constrained by the SHAKE algorithm (or the SETTLE algorithm for water), permitting an 200 
integration time step of 2 fs. Three Production runs of 50 ns were performed for each compound 201 
under NVT (conserved substance (N), volume (V) and temperature (T)) conditions and coordinates 202 
were saved every 1000 simulation steps, producing 75000 total frames per compound.  203 
Secondary structure analysis over time for compounds were calculated using the VMD 204 
timeline plugin (v2.3). Selection of the most representative structures from the simulation trajectories 205 
was based on backbone RMSD clustering in UCSF Chimera 1.8.1 [43], were the frame with the 206 
lowest RMSD relative to the largest cluster was selected. The radius of gyration, surface area and 207 
polar surface area were calculated from the molecular dynamics trajectories using VEGA ZZ 3.03 208 
[44] and a water probe radius of 1.4 Å, and the n-octanol/water partitioning coefficients were 209 
calculated according the vLogP model [45]. 210 
 211 
RESULTS 212 
Design and Agonist Activity of α-Conotoxin cVc1.1 Chimeras 213 
There are currently no small molecule GLP-1R agonists with a similar activation profile to that of the 214 
endogenous agonist GLP-1 [29]. The smallest GLP-1R agonists with similar efficacy to GLP-1 are the 215 
11-residue peptidomimetics, BMS21 and compound 1 (Figure 1B). BMS21 has a central 310-helical 216 
segment across residues 6–11 [28], and compound 1 was expected to have a similar conformation. 217 
Consequently, in our design process the sequence of 1 with the substitution Aib2 (aa6) to Pro2 was 218 
grafted into the helical segment of the engineered cyclotide cVc1.1 [36] (Figure 1C), to produce both 219 
open 2 and backbone cyclic 3 grafted peptidomimetics. The Aib2 residue in 1 was substituted for Pro2 220 
because this residue is important for maintaining the fold of cVc1.1 [46] (Figure 1C and 1E; Table 1). 221 
Comparing GLP-1R activation for the linear starting compound 1 with the monocyclic compound 2 222 
indicated a 6-fold reduction in cAMP signaling (Table 2). Backbone cyclization of 2 produced 223 
bicyclic compound 3, which was accompanied by a 500-fold reduction in cAMP activity. To confirm 224 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
that Aib2 present in 1 was not suitable for the cyclotide cVc1.1 scaffold, Pro2 in 3 was substituted for 225 
Aib2 to produce 4, which was accompanied by >3-fold reduction in potency of cAMP signaling. 226 
To investigate if the reduction in potency, resulting from backbone cyclization of 2 to 3, 227 
related to loss of the N-terminal amine or loss of flexibility, 2 was acetylated at the N-terminus. The 228 
resulting compound 5 was found to have intermediate cAMP potency compared to 2 and 3, suggesting 229 
that both a free N-terminus and N-terminal flexibility are important for receptor activation. During the 230 
optimization of BMS21 it was found that the 2,6-di-fluorine substitution of α-Me-Phe6 (aa10) was a 231 
marginally more potent cAMP activator than the 2-mono-flourine derivative (aa9) [28]. The same 232 
substitution in 2 to produce 6 had a similar marginal effect on cAMP signaling. 233 
Backbone cyclization of 6 to 7 resulted in a larger (>2-fold) loss of cAMP activity. 234 
Substituting α-Me-(2-F)-Phe2 (aa9) in 7 with α-Me-Phe2 (aa8) in 8 caused a further 2-fold reduction 235 
in cAMP signaling. Interestingly, substituting the α-Me-Phe2 in 8 with Phe2 in 9 was accompanied by 236 
a 5-fold recovery of cAMP potency, suggesting that there was interdependency between the α-Me 237 
group and the fluorine(s) in promoting potency. 238 
Subsequently, we wanted to investigate the possibility of increasing the hydrophobicity of 2 239 
and 3 by modifying the cyclization linker in cVc1.1. Residues 15–17 and 19–20 were substituted with 240 
Val residues in the mono- and bicyclic compounds 10 and 11. However, these substitutions were 241 
accompanied by a 20-fold and 2-fold reduction of cAMP signaling, respectively. Similarly, residues 242 
15–20 in 2 and 3 were also substituted for Leu residues, but in conjunction with α-Me-(2-F)-Phe2
 
to 243 
α-Me-Phe2 substitutions, to produce compounds 12 and 13, respectively. The rational for the residue 244 
2 substitution was that this substitution in 8 resulted in a slight improvement in cAMP activity; 245 
however, both 12 and 13 were found to have reduced cAMP potency.  246 
Considering the importance of the biphenyl derivatives in positions 10–11 of BMS21 for 247 
cAMP activity [28], Gly14 in the cVc1.1 linker of 2 and 3 was substituted for biphenyl to give 248 
compounds 14 and 15. These substitutions were well tolerated and only resulted in minor (1.1–2.8-249 
fold) losses of cAMP signaling potency. Compounds 14 and 15 were then substituted with α-Me-Phe
 
250 
at position 2 to produce 16 and 17, respectively. These substitutions had different consequences for 251 
the mono- and bicyclic compounds, with the former losing activity and the latter gaining activity. This 252 
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trend is similar to that seen for 8, where the α-Me-Phe
 
substitution at position 2 was favorable, and it 253 
appears that the bicyclic form of α-Me-Phe2 is more effective than α-Me-(2-F)-Phe2. By grafting 254 
compound 1 into cVc1.1, additional constraints were introduced by the presence of a disulfide bond. 255 
To investigate the effect of further increasing these constraints, Cys12 and Cys21 in 2 and 3 were 256 
substituted with (β,β-di-Me)-Cys (aa7) to produce 18 and 19, and these changes were accompanied by 257 
3–5-fold reductions in cAMP signaling. Thus, it appears that the disulfide bond constraint had a 258 
negative effect on potency. Consequently, Cys12 and Cys21 were substituted with Abu12 and Abu21 259 
(aa5) in the most potent variant, compound 2. The resulting compound 20 showed a 2-fold increase in 260 
potency of cAMP signaling and became the most potent variant. 261 
 262 
Design and Agonist Activity of α-Conotoxin pc16a Chimeras 263 
For the cVc1.1 grafted variants, the sequence of 1 was uninterrupted by disulfide bonds, and thus we 264 
wanted to examine the possibility of constraining the peptidomimetic further by introducing disulfide 265 
bonds within the actual sequence of 1 using the non-cyclic α-conotoxin pc16a. Grafting 1 into pc16a 266 
resulted in 21, where Thr5 and Thr7 were substituted with Cys residues designed to form a disulfide 267 
bond. Compound 21 showed a 3000-fold reduction in cAMP activity. Interestingly, the two bicyclic 268 
compounds, 3 and 21, showed an equal loss of agonist activity irrespective of the scaffold. Further 269 
substitution of α-Me-(2,6-di-fluorine)-Phe6 with α-Me-(2-fluorine)-Phe6 and α-Me-Phe6
 
in 21 to give 270 
compounds 22 and 23 was accompanied by a further 12- and 4-fold reduction in cAMP signaling 271 
potency, respectively, which is more than for the same substitutions in 7. Furthermore, substituting α-272 
Me-(2-fluorine)-Phe6 in 23 for Phe6 resulted in 24 and a further 10-fold reduction in cAMP signaling 273 
potency, a substitution that had a 5-fold positive effect for the comparable substitution in 8. 274 
Interestingly, N-terminal acetylation of 21 to give compound 25 caused a 6-fold increase in potency, 275 
which is the opposite effect seen for the equivalent addition to compound 2, which lost 15-fold in 276 
potency. In compound 21, Leu12 remained from the pc16a scaffold without known function, and was 277 
substituted for a biphenyl residue, but the resulting compound 26 showed a 17-fold reduction in 278 
cAMP signaling.  279 
 280 
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 281 
 282 
Molecular Modeling of α-Conotoxin Chimeras 283 
To gain insight into how grafting of the peptidomimetics into α-conotoxins affected their structure, 284 
selected grafted variants were subjected to 150 ns (3 x 50 ns) molecular dynamics simulations. Since 285 
NMR spectroscopy studies of BMS21 in 70:30 dimethyl sulfoxide:water have been previously 286 
reported [28], the same solvent system was used for the simulations. However, since the atomic 287 
coordinates of the BMS21 structure have not been released, a comparison could only be based on the 288 
published description. BMS21 was found to adopt a 310-helix spanning residues 6–11 (with residues 289 
9–11 being distorted from the canonical conformation) and a distorted type I turn or type VIIa turn 290 
across residues 2–4 with a kink at Aib2.  291 
The model of compound 1 was suggested to have an α-helix spanning residues 3–8 during the 292 
majority of the simulation trajectory and random coil conformations for residues 9–11 and 1–2, with a 293 
distinct kink at Aib2 as for BMS21
 
(Figure 2A and Figure S2). The monocyclic compound 2 model 294 
was nearly identical to 1 across residues 3–10 (Cα R SD: 0.93 Å), with a α-helix spanning residues 295 
3–9, although residues 1–2 were more extended and lacked the residue 2 kink (Figure 2B and Figure 296 
S2). Similarly, the model of the bicyclic compound 3 overlaid closely across residues 3–10 with 1 (Cα 297 
RMSD: 1.06 Å) and 2 (Cα RMSD: 1.11 Å) and displayed comparable structural features across the N-298 
terminal 11 residue segment (Figure 2C and Figure S2). Aligning the models of compound 10 and 11 299 
(Figure 2D and Figure S2) with 1 indicated a strikingly close alignment across residues 3-9 (Cα 300 
RMSD: 0.32 Å and 0.22 Å respectively). However, both the peptide backbone and side chains of 301 
residues 10-11 deviated greatly from compounds 1-3 which may explain the dramatic loss of cAMP 302 
activity for these variants. The modeled structure of compound 20 differed greatly from the other 303 
structures with the lack of any cyclic constraints resulting in mostly a turn motif across the whole 304 
peptide, with some intermittent 310-helix/α-helix tendency across residues 11-13. Compound 21, 305 
which was based on a different α-conotoxin scaffold (pc16a) compared to compounds 2-20 (Vc1.1), 306 
also appeared structurally different with a 310 helical tendency across residues 2-4 with a turn motif 307 
across residues 6-10 (Figure 2E and Figure S2). 308 
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Although 2 and 3 contain twice as many amino acids as 1 and have masses 50% larger than 1, 309 
both had smaller radii of gyration (Rg; Table 3). The additional amino acids in 2 and 3 resulted in 310 
noticeable increases in surface area (SA), polar surface area (PSA), and a lower n-octanol/water 311 
partition coefficient according to the vLogP model [45]. Introducing Val residues in the Ala-Gly 312 
linker of 2 and 3 to produce 10 and 11 reduced the PSA and greatly increased the lipophilicity, as 313 
indicated by the vLogP values. The most potent variant, the non-cyclic compound 20, had the least 314 
favorable biophysical properties with the largest Rg, PSA and SA, and the lowest vLOGp. Compounds 315 
21 and 25, with three more amino acids and a mass ~20% larger than 1, had the smallest Rg of the 316 
peptides examined. Compound 25, the most potent cAMP agonist based on the pc16a scaffold, had a 317 
PSA comparable to 1, but with greatly increased lipophilicity as indicated by the vLogP.  318 
 319 
Perfluorophenylene-Crosslinked Compound 1 Analogues  320 
To further increase hydrophobicity and potentially membrane permeability while maintaining α-321 
helicity in the C-terminal part (residues 6–11) of the parent molecule, we designed a series of stapled 322 
compound 1 analogues based on a recently developed cysteine perfluoroarylation approach [47]. 323 
Previously reported [38] structure-activity data for pharmacophore (1) suggest that substitution of 324 
Thr5, Thr7 and Asp9 as well as C-terminal extensions [32] are well tolerated and may yield molecules 325 
that retain potent GLP1R activation. Pairs of cysteines were introduced in an i, i+4 configuration in 326 
positions 5/9 (27) and 8/12 (28) and were cross-linked by reaction with hexafluorobenzene under mild 327 
conditions in solution, as previously reported (Figure 3). Similarly, compound 29, containing a 328 
perfluorobiphenyl staple (designed to span two α-helical turns), was generated by introducing 329 
cysteines in positions 5 and 12 (i, i+7) and reaction of the unprotected peptide with 330 
decafluorobiphenyl. The resulting molecules displayed a large shift to later RP-HPLC retention times 331 
compared to the non-stapled parent molecules, suggesting significantly increased hydrophobicity and 332 
reduced PSA. This was confirmed by MD simulations where, for example, 27 had the smallest Rg, 333 
PSA and SA as well as the highest vLogP of all compounds investigated (Table 3). The modeled 334 
structure of 27 overlaid very closely with compound 1 across residues 3–9 (Cα RMSD 0.62); 335 
however, the increased N-terminal and C-terminal helicity of 27 resulted in that residues 1–2 and 9–336 
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11 deviated greatly from 1 in both backbone conformation and spatial side chain orientation (Figure 337 
2F and Figure S2), which may account for the reduced cAMP activity.  338 
 339 
CONCLUSIONS 340 
This study has demonstrated that it is possible to produce bicyclic peptidomimetic GLP-1R agonists 341 
that maintain potent cAMP activity. By capitalizing on cyclization patterns optimized through 342 
evolution to maintain certain secondary structure motifs in naturally occurring disulfide-rich α-343 
conotoxins, these motifs were maintained in the cyclic peptidomimetic chimeras. The consequences 344 
of cyclization often included a reduction of the radius of gyration while increasing the overall 345 
lipophilicity, characteristics frequently associated with improved membrane permeability and 346 
bioavailability [48]. These findings open up new avenues for the design of potent bicyclic GLP-1R 347 
agonists. 348 
 It is interesting that, in the process of grafting smaller peptidomimetics into larger cyclic 349 
peptide scaffolds, the radius of gyration can be reduced, which appears to be a direct result of the 350 
additional constraints induced by cyclization. The values estimated for the radius of gyration of 351 
grafted cVc1.1 variants by molecular dynamics correspond well to that previously determined for 352 
wild-type cVc1.1 using pulsed-field gradient NMR (Rg = 7.45 Å [49]). Other consequences of this are 353 
both masking of the polar termini, and that hydrophobic residues are locked in conformations 354 
exposing them to the solvent, resulting in increased molecular hydrophobicity. 355 
An additional beneficial effect of cyclization is stabilization, leading to increased resistance to 356 
chemical, thermal or enzymatic insult; indeed, a number of backbone-cyclized conotoxins have been 357 
reported to share these properties [50-52]. This is also true for cyclotides, a class of plant-derived 358 
disulfide-rich and backbone-cyclized peptides [53, 54]. Recently bioactive peptides were grafted into 359 
the cyclotide kalata B1 scaffold to produce bradykinin B1 receptor antagonists for inflammatory pain 360 
treatment, and these were shown to have an analgesic effect after oral administration in mice [55]. 361 
Similarly, an engineered cyclic version of Vc1.1 (the framework used in the current study) was found 362 
to have oral efficacy in a rat model of neuropathic pain [36]. 363 
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It appears that cyclization through disulfide bonds within the sequence of 1 was much better 364 
tolerated than backbone cyclization; undeniably, all compounds that were cyclized through their 365 
backbone lost potency for cAMP signaling. At the same, time both disulfide and backbone cyclization 366 
appeared to have beneficial effects by reducing the radius of gyration, PSA and SA while increasing 367 
the molecular lipophilicity. Compound 20 showed the most potent cAMP signaling and yet was linear, 368 
but at the same time was estimated to have the least favorable biophysical properties for drug 369 
delivery. This suggests the possibility for temporary constraint of compound 20 in a mono- or bicyclic 370 
pro-drug having properties that initially are similar to 2 or 3. There are a number of approaches 371 
available for introducing temporary bonds that undergo chemical or enzymatic cleavage in vivo to 372 
release the active parent molecule. For example, ester bonds that are cleaved in vivo by esterases have 373 
been used to produce a number of successful pro-drugs with improved lipophilicity, permeability and 374 
bioavailability [56].  375 
We have previously shown that monocyclic analogues of 1 can be potent GLP-1R agonists 376 
[38]. In this study we have demonstrated that it is possible to produce bicyclic, and even more highly 377 
constrained, potent peptidomimetic GLP-1R agonists. Further studies of potential cyclization points 378 
and various substituents are needed to find compounds with properties even more conducive for 379 
increased lipophilicity and permeability, while maintaining potent GLP-1R signaling. Additionally, 380 
these compounds need further evaluation to ensure that the exquisite balance between the various 381 
intracellular signaling pathways is maintained. These highly constrained bicyclic peptidomimetics 382 
may provide an exciting new therapeutic avenue towards the development of GLP-1R agonists with 383 
improved oral bioavailability properties. 384 
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FIGURE LEGENDS 
 
Figure 1: Amino acid sequences and/or structures of incretins, α-conotoxins and peptidomimetics. 
Amino acid sequences of GLP-1 and Ex-4 (A). Chemical structures of BMS21 and compound 1 (B). 
Secondary structures and primary sequences of α-conotoxins cVc1.1 (C) and pc16a (D), with α-
helices shown in green and disulfide bonds in yellow. Peptide segments not present in the naturally 
occurring α-conotoxins are shown in blue. Grafting points are indicated by scissors/dashed lines and 
the direction of the grafted segments are indicated by dashed arrows from the C-terminus to the N-
terminus. (E) Structures of non-natural amino acids used for synthesis of peptidomimetic α-conotoxin 
chimeras. 
Figure 2: Representative simulation structures calculated by molecular dynamics simulations. 
Representative simulation structures of compound 1 (A), compound 2 (B), compound 3 (C), 
compound 10 (D), compound 21 (E) and compound 27 (F), with the left-hand side of each panel 
showing atom stick models (carbon: green; nitrogen: blue; oxygen: red; sulphur: yellow; fluorine: 
white) and the right-hand side of each panel showing the secondary structures (α-helix: green; random 
coil: grey) and disulfide bonds in ball and stick model (carbon: green, sulphur: yellow). 
 
Figure 3: Structures of compound 1 analogues with cysteine perfluoroarylation linkages. The 
structures of compound 1 analogues with varying cysteine perfluoroarylation linkages are shown for 
compound 27 (A), compound 28 (B) and compound 29 (C). 
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Table 1: Sequences of α-conotoxins and grafted peptidomimetic chimeras 
Residuea/ 
Compound 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Modificationb 
α-conotoxin Vc1.1 and peptidomimetic chimerasc 
 
 
cVc1.1 Asp Pro Arg Cys Asn Tyr Asp His Pro Glu Ile Cys Gly Gly Ala Ala Gly Gly Gly Cys Cys Ser Cyclo 
2 His Pro Glu Gly Thr aa10 Thr Ser Asp aa3 aa4 Cys Gly Gly Ala Ala Gly Gly Gly Ala Cys Ser - 
3 His Pro Glu Gly Thr aa10 Thr Ser Asp aa3 aa4 Cys Gly Gly Ala Ala Gly Gly Gly Ala Cys Ser Cyclo 
4 His aa6 Glu Gly Thr aa10 Thr Ser Asp aa3 aa4 Cys Gly Gly Ala Ala Gly Gly Gly Ala Cys Ser Cyclo 
5 His Pro Glu Gly Thr aa10 Thr Ser Asp aa3 aa4 Cys Gly Gly Ala Ala Gly Gly Gly Ala Cys Ser Ac- 
6 His Pro Glu Gly Thr aa9 Thr Ser Asp aa3 aa4 Cys Gly Gly Ala Ala Gly Gly Gly Ala Cys Ser - 
7 His Pro Glu Gly Thr aa9 Thr Ser Asp aa3 aa4 Cys Gly Gly Ala Ala Gly Gly Gly Ala Cys Ser Cyclo 
8 His Pro Glu Gly Thr aa8 Thr Ser Asp aa3 aa4 Cys Gly Gly Ala Ala Gly Gly Gly Ala Cys Ser Cyclo 
9 His Pro Glu Gly Thr Phe Thr Ser Asp aa3 aa4 Cys Gly Gly Ala Ala Gly Gly Gly Ala Cys Ser Cyclo 
10 His Pro Glu Gly Thr aa10 Thr Ser Asp aa3 aa4 Cys Gly Gly Val Val Val Gly Val Val Cys Ser - 
11 His Pro Glu Gly Thr aa10 Thr Ser Asp aa3 aa4 Cys Gly Gly Val Val Val Gly Val Val Cys Ser Cyclo 
12 His Pro Glu Gly Thr aa8 Thr Ser Asp aa3 aa4 Cys Gly Gly Leu Leu Leu Gly Leu Leu Cys Ser - 
13 His Pro Glu Gly Thr aa8 Thr Ser Asp aa3 aa4 Cys Gly Gly Leu Leu Leu Gly Leu Leu Cys Ser Cyclo 
14 His Pro Glu Gly Thr aa10 Thr Ser Asp aa3 aa4 Cys Gly aa1 Ala Ala Gly Gly Gly Ala Cys Ser - 
15 His Pro Glu Gly Thr aa10 Thr Ser Asp aa3 aa4 Cys Gly aa1 Ala Ala Gly Gly Gly Ala Cys Ser Cyclo 
16 His Pro Glu Gly Thr aa8 Thr Ser Asp aa3 aa4 Cys Gly aa1 Ala Ala Gly Gly Gly Ala Cys Ser - 
17 His Pro Glu Gly Thr aa8 Thr Ser Asp aa3 aa4 Cys Gly aa1 Ala Ala Gly Gly Gly Ala Cys Ser Cyclo 
18 His Pro Glu Gly Thr aa10 Thr Ser Asp aa3 aa4 aa7 Gly Gly Ala Ala Gly Gly Gly Ala aa7 Ser - 
19 His Pro Glu Gly Thr aa10 Thr Ser Asp aa3 aa4 aa7 Gly Gly Ala Ala Gly Gly Gly Ala aa7 Ser Cyclo 
20 His Pro Glu Gly Thr aa10 Thr Ser Asp aa3 aa4 aa5 Gly Gly Ala Ala Gly Gly Gly Ala aa5 Ser - 
α-conotoxin pc16a and peptidomimetic chimerasc 
 
 
pc16a - - - Ser Cys Ser Cys Lys Arg Asn Phe Leu Cys Cys - - - - - - - - -NH2 
21 His aa6 Glu Gly Cys aa10 Cys Ser Asp aa3 aa4 Leu Cys Cys - - -  - - - - - 
22 His aa6 Glu Gly Cys aa9 Cys Ser Asp aa3 aa4 Leu Cys Cys - - -  - - - - - 
23 His aa6 Glu Gly Cys aa8 Cys Ser Asp aa3 aa4 Leu Cys Cys - - -  - - - - - 
24 His aa6 Glu Gly Cys Phe Cys Ser Asp aa3 aa4 Leu Cys Cys - - -  - - - - - 
25 His aa6 Glu Gly Cys aa10 Cys Ser Asp aa3 aa4 Leu Cys Cys - - -  - - - - Ac- 
26 His aa6 Glu Gly Cys aa10 Cys Ser Asp aa3 aa4 aa1 Cys Cys - - -  - - - - - 
helix-constrained compound 1 analogues 
27 His aa6 Glu Gly Cys aa9 Thr Ser Cys aa3 aa4 - - - - - - - - - - - -NH2 
28 His aa6 Glu Gly Thr aa9 Thr Cys Asp aa3 aa4 Cys - - - - - - - - - - -NH2 
29 His aa6 Glu Gly Cys aa9 Thr Ser Asp aa3 aa4 Cys - - - - - - - - - - -NH2 
aNon-canonical amino acids are referred to as aaX (where X is a number) and their molecular structures are shown in figure 1E 
bModifications: Cyclo, peptide backbone cyclization; dash (-), uncyclized peptide backbone; -NH2, amidated C-terminus of peptide; Ac, acetylated N-terminus of peptide 
cBlack lines indicate disulfide connectivity.  
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Table 2: Masses and cAMP activities (CHO-GLP-1 cells) of grafted α-conotoxins and peptidomimetic 
chimeras 
Compound Calculated mass (Da) Determined mass (Da) cAMP EC50 (nM) ± SEM n 
1 1482.6 1483.2 0.14 ± 0.01 3 
2 2285.8 2285.8 0.85 ± 0.07 3 
3 2267.9 2268.6 430 ± 40 3 
4 2257.4 2257.2 1400 ± 50 3 
5 2327.0 2327.7 13 ± 0.5 3 
6 2267.9 2268.1 1.0 ± 0.4 3 
7 2250.6 2249.9 1000 ± 30 3 
8 2231.9 2231.8 2000 ± 100 3 
9 2217.9 2219.9 390 ± 40 3 
10 2453.8 2453.1 19 ± 0.5 3 
11 2435.8 2437.0 1000 ± 100 3 
12 2470.9 2471.0 130 ± 40 3 
13 2488.0 2488.5 2800 ± 130 3 
14 2451.1 2452.0 2.4 ± 0.06 3 
15 2433.1 2434.8 470 ± 20 3 
16 2399.0 2399.0 47 ± 2 3 
17 2415.8 2415.5 360 ± 10 3 
18 2342.6 2342.2 2.5 ± 0.2 3 
19 2324.6 2325.9 2000 ± 50 3 
20 2251.5 2251.8 0.47 ± 0.02 3 
21 1803.4 1803.5 430 ± 80 3 
22 1784.0 1784.3 5000 ± 1000 3 
23 1766.7 1767.5 1600 ± 50 3 
24 1752.6 1753.4 16000 ± 700 3 
25 1844.9 1846.5 69 ± 27 3 
26 1914.0 1914.6 7500 ± 1100 3 
27 1600.6 1600.7 850 ± 45 3 
28 1729.6 1729.8 1150 ± 50 2 
29 1863.6 1863.7 >1000 1 
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Table 3: Biophysical parameters calculated from molecular dynamics 
Compound Rg (Å) PSA (Å2) SA (Å2) vLogP 
1 8.2 ± 0.3 492 ± 30 1736 ± 36 0.39 ± 0.04 
2 7.9 ± 0.1 651 ± 32 2138 ± 67 -2.24 ± 0.07 
3 7.8 ± 0.1 636 ± 39 2026 ± 42 -1.16 ± 0.04 
10 7.9 ± 0.1 543 ± 30 2227 ± 48 3.22 ± 0.34 
11 7.8 ± 0.1 512 ± 18 2213 ± 31 3.76 ± 0.33 
20 8.3 ± 0.2 715 ± 26 2377 ± 47 -3.30 ± 0.32 
21 7.1 ± 0.2 577 ± 28 1786 ± 42 0.20 ± 0.06 
25 7.2 ± 0.1 514 ± 25 1831 ± 52 3.14 ± 0.36 
27 7.2 ± 0.2 444 ± 21 1654 ± 44 3.94 ± 0.40 
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Figure S1: 1H NMR spectra of peptides used in this study. Experiments were run on a Bruker 600 
MHz Avance spectrometer at 298K in 12-60% ACN-d3 / H2O. 
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Figure S1: 1H NMR spectra of peptides used in this study (continued). 
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Figure S1: 1H NMR spectra of peptides used in this study (continued). 
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Figure S1: 1H NMR spectra of peptides used in this study (continued). 
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Figure S1: 1H NMR spectra of peptides used in this study (continued). 
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Figure S2: Secondary structure analysis from molecular dynamics trajectories. Plots of calculated 
secondary structures during molecular dynamics simulations over time (x-axis) versus peptidomimetic 
residue number (y-axis) for three replicates of 50 ns simulations (top to bottom). A secondary structure 
color code key is given below. 
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Figure S2: Secondary structure analysis from molecular dynamics trajectories (continued) 
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Figure S2: Secondary structure analysis from molecular dynamics trajectories (continued) 
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Figure S2: Secondary structure analysis from molecular dynamics trajectories (continued) 
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Figure S2: Secondary structure analysis from molecular dynamics trajectories (continued) 
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Figure S2: Secondary structure analysis from molecular dynamics trajectories (continued) 
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Figure S2: Secondary structure analysis from molecular dynamics trajectories (continued) 
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Figure S2: Secondary structure analysis from molecular dynamics trajectories (continued) 
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Figure S2: Secondary structure analysis from molecular dynamics trajectories (continued) 
 
